Kyu-Sik Kim; Jong-Won Chung; Jong-Pil Jeonq; In-Jae Oh; Soo-Ock Kim; Jun-Gwang Son; Yu-il Kim; Sung-Chul Lim; Young-Chul Kim; Kyung-Ok Park

doi:10.6058/jlc.2006.5.1.47

Journal List > J Lung Cancer > v.5(1) > 1050661

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim, Chung, Jeonq, Oh, Kim, Son, Kim, Lim, Kim, and Park: A Case of Pulmonary Thromboembolism Developed during Chemotherapy with Gemcitabine and Cisplatin for Non- small Cell Lung Cancer —A case report —

Original Article

J Lung Cancer 2006;5(1):47-50.

Published online: 18 December 2006

DOI: https://doi.org/10.6058/jlc.2006.5.1.47

A Case of Pulmonary Thromboembolism Developed during Chemotherapy with Gemcitabine and Cisplatin for Non- small Cell Lung Cancer —A case report —

Kyu-Sik Kim, M.D.^1,², Jong-Won Chung, M.D.², Jong-Pil Jeonq, M.D.^1,², In-Jae Oh, M.D.^1,², Soo-Ock Kim, M.D.^1,², Jun-Gwang Son, M.D.^1,², Yu-il Kim, M.D.², Sung-Chul Lim, M.D.², Young-Chul Kim, M.D.^1,^2,, Kyung-Ok Park, M.D.³

¹Yung and Esophageal Cancer Clinic, Chonnam National University Hwasun HsopitaL

²DeDartment of Pulmonolopy and Critical Care Medicine, Chonnam National University Medical School, Gwangiu,

³department of Internal Medicine. St Carollo Hospital, Suncheon, Korea

Address for correspondence Young-Chul Kim, MIX Lunq and Esoohaaeal Cancer Clinic, Chonnam National University Hwasun HsopitaL 160, llsim-ri, Hwasun-eup, Hwansun 519-809, Korea Tel: 82.61-379-7614 Fax: 82-61-379-7628 E-mail: kyc0923@jnu.ao.kr

Received 4 May 2006 Accepted 30 May 2006

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Lung cancer patients have increased risk of thromboembolism (TE) due to various factors such as by hypercoagulability, tumor thrombosis, decrease of ambulation, arid chemotherapy etc. Among these factors, chemotherapy associated TEs have been reported, although the causes and pathomechanisms of TEs were not clear. Recently, reports proposed the potential role of platelets in endothelial damage by the chemotherapeutic agents. We have experienced a case of pulmonary TE after systemic chemotherapy with gemcitabine and cisplatin. The patient complained aggravated exertional dyspnea after chemotherapy and diagnosed as pulmonary TE by computerized tomogram. After anticoagulation and interruption of the chemotherapy, improvement of exertional dyspnea and resolution of the pulmonary TE were observed. (J Lung Cancer 2006;5(1):47-50)

Keywords: Gemcitabine, Thromboembolism, Lung cancer

REFERENCES

1.Nadir Y., Hoffman R., Brenner B, et al. Drug-related thrombosis in hematologic malignancies. Ref Clin Exp Hematol. 2004. 8:E4.

2.Kuenen BC., Rosen L., Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002. 20:1657–1667. ,.

3.Holmgren L., O'Reilly MS., Folkman J. Dormancy of micro. metastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995. 1:149–153.

4.Dvorak HF., Brown LF: Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995. 146:1029–1039.

5.Carmeliet P: Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000. 407:249–257.

6.Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995. 1:27–31.

7.Engels K: Fox SB., Harris AL. Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. EXS. 1997. 79:113–156.

8.Abulafia 0., Triest WE., Sherer DM. Angiogenesis in malignancies of the female genital tract. Gynecol Oncol. 1999. 72:220–231.

9.Seo Y., Baba H., Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000. 88:2239–2245.

10.Shih CH: Ozawa S., Ando N, et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2000. 6:1161–1168.

11.Takanami I., Tanaka F., Hashizume T, et al. Vascular endothelial growth factor and ks receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 1997. 17:2811–2814.

12.Benjamin LE. The controls of microvascular survival. Cancer Metastasis Rev. 2000. 19:75–81.

13.Kuenen BC., Levi M., Meijers JC, et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin: gemcitabine: and the angiogenesis inhibitor SU5416. J Clin Oncol. 2003. 21:2192–2198.

14.Numico G., Garrone 0., Doniovanni V, et al. Prostpective evaluation of major vascular events in patients with non small cell lung carcinoma treated with cisplalin and gemcitabine. Cancer. 2005. 103:994–999.

15.Crino L: Scagliotti G., Marangolo M, et al. Cisplatin-Gemcitabine combination in advanced non small cell lung cancer: a phase II study. J Clin Oncol. 1997. 15:297–303.

16.Rosen P., Kabbinavar F., Figlin R, et al. A phase I/II trial and pharmacokinetic study of SU5416 in combination with paclitaxel/carboplatin. Proc Am Soc Clin Oncol. 2001. 20:98a. (abstr 389).

17.Schiller JH: Harrington D: Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002. 10(346):92–98.

Fig. 1.

Chest computed tomogram obtained on initial visit. 5 cm diameter necrotic mass and mediastinal lymphadenopathy were observed.

Fig. 2.

Chest computed tomogram obtained after 3 cycles of gemcitabine and cisplatin chemotherapy showed thrombi in right main pulmonary artery.

Fig. 3.

Chest computed tomogram obtained 6 months after anticoagulation therapy showing resolution of thrombi in the right main pulmonary artery.

TOOLS

Similar articles